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Formulations of piroxicam in Lanette® (L) or Net Fs® (N) vehicles,
with or without permeation enhancers, the ethanol (E) or propylene
glycol (P) were developed. The piroxicam permeation through
porcine ear skin, in a Franz Cell was evaluated, comparing with a
commercial product. The permeate was analyzed by high
performance liquid chromatography (HPLC) using a 5 mm C18
column with mobile phase methanol:phosphate buffer (60:40), at
354 nm and the run time of 10 min. This method was validated and
the limit of quantification was 0.138 μg/mL, with linearity over
0.02-5 μg/mL, without endogenous skin interference. The order of
piroxicam permeation after 24 h was: LE > L> Feldene® > N >
LP > NP > NE. The L based formulations showed greater piroxicam
permeation compared with N based formulations, particularly up
to 10 h of experiment. The ethanol enhancer provided the highest
piroxicam permeation. The commercial product shows a different
behavior, providing piroxicam permeation almost after 10 h. These
results show the development of effective, simple and economic
percutaneous formulations of piroxicam allowing the choice of
formulations for higher or lower piroxicam permeation.
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1,2-benzothiazine-3-carboxamide-1,1-di-oxide) is a non
steroidal anti-inflammatory and analgesic agent. This
drug has been widely used in the treatment of rheumatoid
arthritis and other inflammatory disorders (Insel, 1991).
It is well absorbed following oral administration however
its use has been associated with a number of undesirable
side effects on the stomach and kidneys in addition to
gastric mucosal damage (Babar, Solanki, Cutie, 1990).
These side effects may be overcome through topical
administration of the drug (Schiantarelli et al., 1982). For
this reason piroxicam is commercialized in topical
products in a gel form.
The percutaneous absorption of drugs involves two
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consecutive processes: the release of the drug from the
topical formulation, and its absorption into and through the
skin, at the application site (Shima et al., 1981). One of the
strategies used to decrease the barrier function of stratum
corneum is enhancers.
Considerable research is currently being carried out,
on chemical penetration enhancers, in order to improve
drug penetration, and conventional substances may be used
for this purpose (Barry, 1983; Martins, Veiga, 2002) as
ethanol (Sloan et al., 1998; Zhao, Shing, Shing, 2001;
Heard, Kung, Thomas, 2006) and propylene glycol
(Santoyo et al., 1995; Gao, Singh, 1998; Bowen, Heard,
2006). Penetration enhancers that interact with lipids of the
outermost layer of the skin allow better penetration of co-
administered drugs (Cheong, Choi, 2003).
The principal purpose of this work is to develop an
effective, simple, and economic percutaneous formulation
of piroxicam, which can be produced in a compounding
pharmacy, using conventional excipients and comparing
the in vitro percutaneous absorption of these formulations
with commercial available products. The suitability of the
HPLC method for quantifying piroxicam in vitro
percutaneous permeation study was demonstrated.
MATERIAL AND METHODS
Reagents, materials and standard solution
The materials used, in accordance with
pharmaceutical purity grade, were: cetostearyl alcohol,
sodium lauryl sulphate - Lanette® (Natural Farma), decyl
oleate - Cetiol V, BHT, EDTA Na2, ciclometicon - Silicon DC
245® and Sorbitol (purchased from All Chemistry), silicone
microemulsion - Net Fs® (Galena), piroxicam (DEG,
99.5%), propylene glycol (Nuclear), Nipagim®, Nipazol®
and cetoestearyl alcohol (purchased from Purifarma),
Natrosol® (Vital), mono glyceryl monoestearate (Croda),
Triethanolamine and carbomer- Carbopol ETD 2020®
(Dinaco). The solvents used for the analytical analyses were
of chromatographic grade and were purchased from JTBaker
(Phillipsburg, USA). All the others chemicals used were of
reagent grade. The commercial product used was Feldene®
0.5% gel (Pfizer, Brazil).
A 500 μg/mL stock solution of piroxicam in 0.01 M
methanolic hydrochloric acid was diluted to 10 μg/mL as
follows: 1 mL of stock solution was transferred to a
volumetric flask of 50 mL and 25 mL of 0.01 M methanolic
hydrochloric acid were added, followed by 10 mL of
ultrapure water, and the total volume was completed with
0.01 M methanolic hydrochloric acid. Six standard
solutions (0.02 to 5 μg/mL) were prepared by further
dilution of the 10 μg/mL stock solution, with appropriated
volumes of 0.01 M methanolic hydrochloric acid. The
piroxicam solutions were freshly prepared, each day.
Apparatus and chromatographic conditions
The apparatus used for the HPLC analysis was a
Shimadzu (Tokyo, Japan) chromatographic system equipped
with Shimadzu LC 10AD-VP binary pump and Shimadzu
SPD M10A 354 nm photo diode array detector. Samples
were injected using a Rheodyne 7725i, manual injector
(Rohnert Park, C.A., USA), at 1.2 mL/min flow, using a
Phenomenex column (Luna RPC18, 5 mm, 4.6 x 250 mm),
and a Shimadzu CTO-10A column over fit to 35 °C.
The mobile phase consisted of 60:40 methanol:buffer
in an isocratic elution. The buffer consisted of 7.72 g
anhydrous citric acid in 400 mL of water, and 5.35 g of
dibasic sodium phosphate, separately dissolved in 100 mL
of water. The phosphate solution was added to the citric
acid solution, diluted with water to make 1000 mL, and
mixed. Solvents of HPLC were degassed by N2 gas, prior
to use, and filtered through 0.45 mm regenerated cellulose
membranes by vacuum. Data acquisition and integration
were carried out using Shimadzu Class VP software (5.032
version).
HPLC assay
The piroxicam assay method in the permeated fluids
was adapted to its raw material monography (United States
Pharmacopeia, 2006), with the follow changes: the suggested
wavelength of 254 nm was changed to 354 nm, in view of the
higher absorbance, and the organic phase of the mobile phase
was increased, in order to decrease the analysis time. The
analytical procedure was submitted to validation (Brasil,
2003), to demonstrate its suitability for analyzing the
piroxicam in this transdermal permeation study.
The linearity was verified using concentrations of
0.02, 0.05, 0.5, 1, 2 and 5 μg/mL of piroxicam, dissolved
in 0.01 M methanolic hydrochloric acid, in triplicate.
For the analysis of assay specificity, the retention
times of the endogenous compounds in the matrix were
compared with those of the piroxicam.
The precision of the method was tested within-day and
between-day of the assay. Precision was expressed as the
relative standard deviation (RSD) of replicate measurements.
This study was developed with three concentrations (0.05,
0.5 and 2 μg/mL) of piroxicam in 0.1 M methanolic
hydrochloric acid. Each concentration was assayed in
triplicate, on the same day and on the other two different
days, in triplicate.
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The accuracy of the assay method was defined as the
recovery percentage, by the assay of known added amount
of analyte (2 μg/mL) in a permeated sample (LE), in
triplicate. The sample was previously divided into two
aliquots, and the piroxicam present in the permeated sample
was subtracted from the sample spiked with the analyte.
The limit of quantification (LOQ) was calculated by
the follow equation:
LOQ = 10 S/a
where S is the standard deviation of linear coefficient of the
calibration curve and a is the angular coefficient of the
calibration curve.
Preparation of Piroxicam Formulations
The piroxicam formulations are shown in Table I.
The components of formulations containing
Lanette® were prepared by heating to 80 °C i) the
hydrophobic components over continuous stirring; and ii)
the hydrophilic components with 50% of water, also over
continuous stirring. Next, i) was added to ii) over stirring
at 80 °C, for 10 min. To the resultant emulsion, a further
50% of water at room temperature was added, over
continuous stirring. The silicon was added after emulsion
at 40 °C. The Lanette® based formulation was designated
LP and LE, due to the corresponding propylene glycol and
ethanol enhancers, respectively. No enhancer was added to
the L formulation.
The formulations containing Net FS® were prepared by
mixing all the hydrophobic and hydrophilic components at
room temperature, over continuous stirring. Triethanolamine
was added to allow a pH of 7.0, and then, the Net FS® was
added slowly, followed by continuous stirring, to achieve the
desired viscosity and homogeneity. The Net FS® formulations
were also designated NP, NE and N as described above.
These formulations (Table I) were selected after a
trial using various formulations, submitted to stress tests
with freezing-defrosting cycles (data not show), followed
by centrifugation with analysis of the organoleptic
characters, appearance, pH and viscosity. The six
formulation selected (LP, LE, L, NP, NE and N), shown in
Table I, were finally submitted and approved in a stability
study at 25 and 40 °C for 4 months (data not shown).
Skin Preparation
Porcine ears obtained from a local slaughterhouse,
were cleaned under cold running water and the outer region
of the ear was cut. The whole skin was cut, and using a
surgical blade, the skin from the outer surface of a freshly
excised ear was carefully dissected to remove the fat and
blood vessels, and immediately frozen for use within one
month. Slice thickness ranged from 2.0 to 2.5 mm.
In vitro piroxicam permeation
The diffusion cell used was similar to the Franz
diffusion assembly. The excised porcine ear membrane was
TABLE I - Compounding percutaneous formulations of piroxicam
Components %
LP LE L NP NE N
Piroxicam 0.5 0.5 0.5 0.5 0.5 0.5
Lanette N® 5 5 5 - - -
Net FS® - - - 1 1 1
Propylene glycol 10 - - 10 - -
Ethanol - 10 - - 10 -
Glyceryl Monoestearate 5 5 5 - - -
Cetiol V® 2.5 2.5 2.5 - - -
Cetoestearyl alcohol 5 5 5 - - -
Natrosol® 1 1 1 - - -
Ciclometicon DC 245® 3 3 3 3 3 3
Carbopol ETD 2020® - - - 1 1 1
Triethanolamine - - - qsp qsp qsp
Purified Water 67.6 67.6 77.6 84.1 84.1 94.1
Appearance* O/H O/H O/H T/H T/H T/H
*O = opaque; H = homogeneous; T = transparent.
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set in place with the stratum corneum facing the donor
compartment and the dermis side facing the receptor. Two
milliliters of percutaneous formulation was measured with
a syringe and transferred to the skin surface in the donor
compartment, which was sealed from the atmosphere with
a plastic film (parafilm®). The receptor compartment of the
cell was filled with 10 mL of phosphate buffer (pH 7.4).
During the experiments, the solution in the receptor
compartment was kept at 37 ± 0.5 °C by thermostatically
controlled water, and stirred with teflon-coated magnetic
stirring bars. Each experiment was carried out in triplicate.
Samples (1 mL) were removed from the receptor
compartment at regular intervals, and an equal volume of
fresh phosphate buffer (pH 7.4) was added. The samples
were assayed using HPLC.
The diffusional area of cell (ranged from 1.73-1.78 cm2)
was taken into account for the calculation of piroxicam
permeation.
Piroxicam steady state flux (J) was estimated from
the slope of the straight line portion of the cumulative
amount of drug per area (A) against time profiles (Florence,
Attwood, 2003). Different kinetics modes, as Higuchi
(Higuchi, 1961), first order and zero order were applied to
observe the better fit of curves.
RESULTS AND DISCUSSION
In this paper we describe the in vitro permeation
study of percutaneous piroxicam formulations accessible
to compounding pharmacy, with two different enhancers,
comparing these with a commercial product. In addition, a
practical, rapid and suitable assay method is suggested for
analyzing the piroxicam permeated through the porcine ear
skin.
It is emphasized that the method for quantification of
drugs from the samples obtained in permeation in vitro
studies must be specific, since the samples are frequently
contaminated with endogenous skin compounds. In
addition, these methods must also be sensitive, due to the
low concentration of the piroxicam in the aliquots of the
skin permeation studies (Doliwa et al., 2001a). These
authors reported a method by RP HPLC for determining
piroxicam in the transdermal permeation study. However,
a special pH-stable column (Scharlau C18 of 12 x 0.26 cm)
was used, allowing a pH of 2.8 of the mobile phase, in
which the piroxicam is fully unionized (pKa 1 = 1.86).
In the piroxicam assay method developed in the
present work, with a conventional RP column, the
substance has a retention time of 6.2 min (Figure 1). As
shows Figure 1, the skin compounds and the formulations
did not interfere with the analysis of piroxicam. There was
clear resolution of the compound of interest (R = 20)
without any endogenous source of interference.
The assay shows linearity between the area (y) and
the corresponding piroxicam concentration (x) over 0.02-
5 μg/mL range (typical equation, y = 53828x + 122.9). The
result by least-squares linear regression analysis of curves
(n = 3) was > 0.999. The RSD of each point of calibration
standard was < 10%. Doliwa et al. (2001a) reported
linearity to piroxicam HPLC assay in the range of 0.05-
9 μg/mL, with R > 0.994.
The calculated LOQ of piroxicam was 0.138 μg/mL
and the results for within-day and between-day precision
are show in Table II. The RSD values were < 10% in both
cases, and lower at the higher concentrations. The RSD of
the lower concentration is > 3%, probably due to this value
is < LOQ of 0.138 μg/mL. These results are similar to those
found by Doliwa et al. (2001a).
FIGURE 1 - Permeated sample of LE formulations after 4, 7 and 10 h.
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The accuracy of the method after standard addition
in a permeated sample is showed Table III and is within
acceptable limit.
The method for piroxicam assay in the percutaneous
permeation study proved to be suitable, even with a
conventional HPLC RP column. The results for piroxicam
permeation from the different formulations are shown in Fi-
gure 2.
The piroxicam (pK2 5.1) (Drug Information, 1988)
is a slightly lipophilic drug (Doliwa et al., 2001b), with log
P of 1.2466 (Pénzes et al., 2005) commonly vehiculed in
hydrophilic matrices, as a gel-type. A good potency of
penetration is most probable when log P is close to 2
(Beetge et al., 2000) so, the addition of enhancers, ethanol
and propylene glycol, is interesting in view of increase the
drug permeation. Other drugs with a similar balanced
lipophilic/hydrophilic character, as ketoprofen, showed a
flux remarkably enhanced when 2% of alcohol terpen
(menthol) was applied (Nakamura et al., 1996) and this
effect was attributed to the change of dense barrier of
stratum corneum of the skin by the menthol.
In this work, all the formulations showed a similar
piroxicam permeation profile, through the porcine ear skin,
however, the LE formulation presented faster and higher
permeation, compared with other products (Figure 2). The order
of piroxicam permeation was: LE > L> Feldene® > N > LP >
NP > NE. Comparing the emulgent agents used, the Lanette N®
showed higher drug permeation than Net FS®. This could be
explained by the barrier role of Net FS®, a silicon
microemulsion (Zhai, Maibach, 2003) which may decrease
piroxicam transport. On the other hand, the vehicle Lanette is an
anionic matrix of a lipophilic nature, which enhances piroxicam
permeation. The higher drug permeation by the use of anionic
tensoactive may be attributed to the increase of lipid fluidization
in the stratum corneum, due to the fatty alcohols in its
composition (Kitagawa, End, Kameteni, 1985), and also, to the
effect over queratin helix, allowing reversible denaturation that
forms cavities and loss of water absorption ability (Santos,
Bahia, 1995; Bronaugh, Franz, 1986; Nokhodchi et al., 2003).
In addition, even without enhancer (L), Lanette N®
allowed similar piroxicam permeation to the commercial
product. The latter is a carbomer gel, in which the
piroxicam is solubilized in benzilic alcohol and ethanol,
which may be responsible for enhancing the piroxicam
permeation in this product (Barry, Williams, 2004).
In the formulations, the ethanol showed a major
enhancing effect. Ethanol is a potent solvent for both polar
and non-polar species, and it is feasible that a small amount
of ethanol is capable of leaching significant quantities of
non-covalent bound amphiphilic stratum corneum lipids
(Bommannan, Potts, Guy, 1991), which would have the
effect modulating the skin barrier. On the other hand, the
different solubilities of piroxicam in ethanol and propylene
glycol may play a role, affecting permeation of the drug.
Also, the higher viscosities of N based formulations (3,966
and 2,805 mPa.s for NP and NE, respectively) in
comparison with L based formulations (3,175 and
2,405 mPa.s for LP and LE, respectively), may affect the
drug diffusion from product to the exterior, to be able to
penetration in the skin. The N based formulations showed
higher viscosity, probably due to the Net Fs® contribution
(Garcia, Rubio, Aliaga, 1998), and the enhancer ethanol,
that provided the higher permeation of piroxicam, showed
an effect of decrease both formulations viscosity values.
TABLE III - Analysis of accuracy of the HPLC method for
piroxicam assay after transdermal permeation experiments
Concentration Concentration founded Accuracy
added (μg/mL) (mean ± S.D.) (%)
(μg/mL)
no added 0.096 ± 0.009 -
2 2.049 ± 0.051 2.4
TABLE II - Analysis of within-day and between-day
precision of the HPLC method for assay piroxicam
Theoretical within-day between-day
concentration variability variability




FIGURE 2 - In vitro permeation of piroxicam of different
formulations.
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The Table IV shows the kinetics parameters of in
vitro percutaneous permeation of piroxicam from the
different formulations, using the model of zero order, first
order and Higuchi.
For all the formulations, the piroxicam in vitro
permeation showed better fit with zero order kinetics (Table
IV), characteristic of formulations of infinite doses (Wester,
Maibch, 1989). The order of piroxicam flux values at
steady state from the formulations was the same observed
in Figure 2, LE > L> Feldene® > N > LP > NP > NE. The
enhancing ratio of ethanol in the Lanette formulations was
1.9, however, no enhancing effect was observed for the Net
Fs® formulations, for both components, ethanol and
propylene glycol.
CONCLUSIONS
Lanette® based formulations showed greater piroxicam
permeation through the porcine ear membrane, compared with
Net FS® based formulations, particularly up to 10 h of
experiment. In the Net FS® based formulations, the ethanol
and propylene glycol decreased the piroxicam permeation
close to 24 h, in relation to the absence of these enhancers,
without significant increase in the drug permeation after 10 h.
The commercial product presented a different piroxicam
permeation behavior, which showed an increase after 10 h. The
two enhancers used showed different effects, depending on the
vehicle used in the piroxicam permeation, and the final rate of
piroxicam permeation was dependant on the contribution of
the various components of the final formulation, providing
compounding formulations with higher or lower piroxicam
permeation in comparison to the commercial product.
RESUMO
Efeito de promotores na absorção percutânea in vitro
do piroxicam a partir de formulações magistrais
Formulações de piroxicam com base Lanette® (L) ou Net
Fs ® (N), com ou sem promotores de absorção (etanol-E
ou propilenoglicol-P), foram desenvolvidas. O estudo de
permeação de piroxicam das formulações foi realizado em
célula de Franz, usando pele de porco e o desempenho foi
comparado com a especialidade farmacêutica. O fármaco
permeado foi analisado por método desenvolvido por
CLAE usando uma coluna analítica C18 de 15 x 0,46 cm,
com fase móvel metanol: tampão fosfato (60:40), compri-
mento de onda de 354 nm e o tempo de corrida foi de
10 min. O ensaio foi validado e apresentou limite de
quantificação de 0,138 μg/mL , linearidade na faixa de
0,02-5 μg/mL e não ocorreu interferência de substâncias
endógenas da pele ou da formulação. A ordem de
permeação de piroxicam, após 24 horas, foi LE > L>
Feldene® > N > LP > NP > NE. As formulações com L
mostraram maior permeação de piroxicam quando com-
parado com as formulações de base N. Entre os promoto-
res, o etanol promoveu a maior permeação do fármaco.
Os resultados mostraram o desenvolvimento de formula-
ções tópicas econômicas, de fácil obtenção, com efetiva
permeação de piroxicam possibilitando a escolha de for-
mulações com maior ou menor permeação do fármaco.
UNITERMOS: Piroxicam/permeação. Permeação
cutânea. Promotor químico. Etanol. Propilenoglicol. Va-
lidação analítica.
Table IV - Kinetics parameters of in vitro piroxicam permeation from formulations, at steady-state
Formulation Zero order First order Higuchi
J (µg/cm2/h) R2 J (µg/cm2/h) R2 J (µg/cm2/h) R2
LP 0.21 0.9730 5.53 0.9158 1.49 0.9599
LE 0.81 0.9882 20.74 0.8887 5.65 0.9562
NP 0.19 0.9885 4.78 0.8787 1.31 0.9524
NE 0.15 0.9999 3.92 0.9333 10.06 0.9844
L 0.42 0.9596 10.49 0.8105 2.91 0.9036
N 0.29 0.9751 7.44 0.8425 2.05 0.9276
Feldene® 0.41 0.9454 10.23 0.7855 2.85 0.8840
J = flux; R2 = correlation coefficient
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